Abstract 4619: Integrated genomic analysis of Hurthle cell carcinoma reveals TMEM233/PRKAB1 fusion as a novel oncogenic driver
Yiyu Dong(Memorial Sloan Kettering Cancer Center), Timothy A. Chan(Cleveland Clinic), Venkatraman Seshan(Memorial Sloan Kettering Cancer Center), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Shyamprasad Vasudeva Deraje(Memorial Sloan Kettering Cancer Center), Eric J. Sherman, Vladimir Makarov, Ian Ganly(Memorial Sloan Kettering Cancer Center), James A. Fagin(Memorial Sloan Kettering Cancer Center), Ed Reznik(Icahn School of Medicine at Mount Sinai), Luc G.T. Morris(Memorial Sloan Kettering Cancer Center), Fengshen Kuo(Memorial Sloan Kettering Cancer Center), Ronald Ghossein(Memorial Sloan Kettering Cancer Center), Nadeem Riaz(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k